schliessen

Filtern

 

Bibliotheken

Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.

BACKGROUNDCisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a prev... Full description

Journal Title: Cancer April 15, 2014, Vol.120(8), pp.1187-1193
Main Author: Nogueira-Rodrigues, Angelica
Other Authors: Moralez, Giulliana , Grazziotin, Rachele , Carmo, Claudio C , Small, Isabele A , Alves, Flavia V G , Mamede, Marcelo , Erlich, Felipe , Viegas, Celia , Triginelli, Sergio A , Ferreira, Carlos G
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1097-0142 ; DOI: 10.1002/cncr.28471
Link: http://search.proquest.com/docview/1514430433/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1514430433
title: Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
format: Article
creator:
  • Nogueira-Rodrigues, Angelica
  • Moralez, Giulliana
  • Grazziotin, Rachele
  • Carmo, Claudio C
  • Small, Isabele A
  • Alves, Flavia V G
  • Mamede, Marcelo
  • Erlich, Felipe
  • Viegas, Celia
  • Triginelli, Sergio A
  • Ferreira, Carlos G
subjects:
  • Adult–Therapeutic Use
  • Aged–Administration & Dosage
  • Antineoplastic Combined Chemotherapy Protocols–Adverse Effects
  • Brachytherapy–Antagonists & Inhibitors
  • Chemoradiotherapy–Administration & Dosage
  • Cisplatin–Adverse Effects
  • Erbb Receptors–Administration & Dosage
  • Erlotinib Hydrochloride–Adverse Effects
  • Female–Mortality
  • Humans–Pathology
  • Middle Aged–Therapy
  • Neoplasm Staging–Therapy
  • Protein Kinase Inhibitors–Therapy
  • Quinazolines–Therapy
  • Uterine Cervical Neoplasms–Therapy
  • Abridged
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • Erbb Receptors
  • Cisplatin
  • Cervical Cancer
  • Chemotherapy
  • Clinical Trial
  • Erlotinib
  • Phase 2
  • Radiotherapy
ispartof: Cancer, April 15, 2014, Vol.120(8), pp.1187-1193
description: BACKGROUNDCisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous...
language: eng
source:
identifier: E-ISSN: 1097-0142 ; DOI: 10.1002/cncr.28471
fulltext: fulltext
issn:
  • 10970142
  • 1097-0142
url: Link


@attributes
ID1357076079
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1514430433
sourceidproquest
recordidTN_proquest1514430433
sourcesystemPC
pqid1514430433
galeid366849229
display
typearticle
titlePhase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
creatorNogueira-Rodrigues, Angelica ; Moralez, Giulliana ; Grazziotin, Rachele ; Carmo, Claudio C ; Small, Isabele A ; Alves, Flavia V G ; Mamede, Marcelo ; Erlich, Felipe ; Viegas, Celia ; Triginelli, Sergio A ; Ferreira, Carlos G
contributorNogueira-Rodrigues, Angelica (correspondence author) ; Nogueira-Rodrigues, Angelica (record owner)
ispartofCancer, April 15, 2014, Vol.120(8), pp.1187-1193
identifierE-ISSN: 1097-0142 ; DOI: 10.1002/cncr.28471
subjectAdult–Therapeutic Use ; Aged–Administration & Dosage ; Antineoplastic Combined Chemotherapy Protocols–Adverse Effects ; Brachytherapy–Antagonists & Inhibitors ; Chemoradiotherapy–Administration & Dosage ; Cisplatin–Adverse Effects ; Erbb Receptors–Administration & Dosage ; Erlotinib Hydrochloride–Adverse Effects ; Female–Mortality ; Humans–Pathology ; Middle Aged–Therapy ; Neoplasm Staging–Therapy ; Protein Kinase Inhibitors–Therapy ; Quinazolines–Therapy ; Uterine Cervical Neoplasms–Therapy ; Abridged ; Protein Kinase Inhibitors ; Quinazolines ; Erlotinib Hydrochloride ; Erbb Receptors ; Cisplatin ; Cervical Cancer ; Chemotherapy ; Clinical Trial ; Erlotinib ; Phase 2 ; Radiotherapy
descriptionBACKGROUNDCisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1514430433/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Nogueira-Rodrigues, Angelica
1Moralez, Giulliana
2Grazziotin, Rachele
3Carmo, Claudio C
4Small, Isabele A
5Alves, Flavia V G
6Mamede, Marcelo
7Erlich, Felipe
8Viegas, Celia
9Triginelli, Sergio A
10Ferreira, Carlos G
titlePhase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
descriptionBACKGROUNDCisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous...
subject
0Adult–Therapeutic Use
1Aged–Administration & Dosage
2Antineoplastic Combined Chemotherapy Protocols–Adverse Effects
3Brachytherapy–Antagonists & Inhibitors
4Chemoradiotherapy–Administration & Dosage
5Cisplatin–Adverse Effects
6Erbb Receptors–Administration & Dosage
7Erlotinib Hydrochloride–Adverse...
8cervical cancer
9chemotherapy
10clinical trial
11erlotinib
12phase 2
13radiotherapy
general
0English
110.1002/cncr.28471
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1514430433
issn
010970142
11097-0142
rsrctypearticle
creationdate2014
addtitleCancer
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorNogueira-Rodrigues, Angelica
startdate20140415
enddate20140415
citationpf 1187 pt 1193 vol 120 issue 8
lsr30VSR-Enriched:[pqid, galeid, issn]
sort
titlePhase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
authorNogueira-Rodrigues, Angelica ; Moralez, Giulliana ; Grazziotin, Rachele ; Carmo, Claudio C ; Small, Isabele A ; Alves, Flavia V G ; Mamede, Marcelo ; Erlich, Felipe ; Viegas, Celia ; Triginelli, Sergio A ; Ferreira, Carlos G
creationdate20140415
lso0120140415
facets
frbrgroupid5024873648314143805
frbrtype5
newrecords20181218
languageeng
creationdate2014
topic
0Adult–Therapeutic Use
1Aged–Administration & Dosage
2Antineoplastic Combined Chemotherapy Protocols–Adverse Effects
3Brachytherapy–Antagonists & Inhibitors
4Chemoradiotherapy–Administration & Dosage
5Cisplatin–Adverse Effects
6Erbb Receptors–Administration & Dosage
7Erlotinib Hydrochloride–Adverse...
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Nogueira-Rodrigues, Angelica
1Moralez, Giulliana
2Grazziotin, Rachele
3Carmo, Claudio C
4Small, Isabele A
5Alves, Flavia V G
6Mamede, Marcelo
7Erlich, Felipe
8Viegas, Celia
9Triginelli, Sergio A
10Ferreira, Carlos G
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Nogueira-Rodrigues
1Moralez
2Grazziotin
3Carmo
4Small
5Alves
6Mamede
7Erlich
8Viegas
9Triginelli
10Ferreira
aufirst
0Angelica
1Giulliana
2Rachele
3Claudio C
4Isabele A
5Flavia V G
6Marcelo
7Felipe
8Celia
9Sergio A
10Carlos G
au
0Nogueira-Rodrigues, Angelica
1Moralez, Giulliana
2Grazziotin, Rachele
3Carmo, Claudio C
4Small, Isabele A
5Alves, Flavia V G
6Mamede, Marcelo
7Erlich, Felipe
8Viegas, Celia
9Triginelli, Sergio A
10Ferreira, Carlos G
addauNogueira-Rodrigues, Angelica
atitlePhase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
jtitleCancer
risdate20140415
volume120
issue8
spage1187
epage1193
pages1187-1193
eissn1097-0142
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDCisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous...
doi10.1002/cncr.28471
urlhttp://search.proquest.com/docview/1514430433/
issn0008543X
date2014-04-15